Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Eccogene of Shanghai Completes $14.6 Million Funding Led by Sinopharm

publication date: Sep 6, 2018

Eccogene Biotechnology of Shanghai completed a $14.6 million Series A round led by Sinopharm Capital The company, which was established in January 2018, focuses on new-generation small molecule novel drugs that meet clinical needs at an affordable cost. The company is led by Jingye Zhou, Co-founder and CEO, who previously worked at Lilly and GlaxoSmithKline. Eccogene has established its own drug R&D team, through it plans to use the services of CRO, CMO and clinical research platforms. More details....

Stock Symbols: (NYSE: LLY) (NYSE: GSK)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.